Marker Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 16.34M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreat...